Malaria killed over 600,000 people in 2022, a death toll that has not improved since 2015.
Additionally, parasites and mosquitoes resistant to existing interventions are spreading …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

Malaria transmission-blocking vaccines (TBVs) aim to elicit human antibodies that inhibit
sporogonic development of Plasmodium falciparum in mosquitoes, thereby preventing …

Summary Pfs230 domain 1 (Pfs230D1) is an advanced malaria transmission-blocking
vaccine antigen demonstrating high functional activity in clinical trials. However, the …

Malaria transmission-blocking vaccines (TBVs) reduce disease transmission by breaking the
continuous cycle of infection between the human host and the mosquito vector. Domain 1 …

Malaria caused by the Plasmodium vivax parasite is a major global health burden. Immunity
against blood-stage infection reduces parasitemia and disease severity. Duffy-binding …

Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein
targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior …

Malaria is a global infectious disease that remains a leading cause of morbidity and mortality
in the developing world. Multiple environmental and host and parasite factors govern the …

A malaria vaccine that blocks parasite transmission from human to mosquito would be a
powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in …

Pfs25 is a leading antigen for a malaria transmission-blocking vaccine and shows moderate
transmission-blocking activity and induction of rapidly decreasing antibody titers in clinical …